scholarly journals An Unusual Instrumentation-Related S1 Radiculopathy in a Patient Treated for a Primary Vertebral (L3) Lymphoma

2012 ◽  
Vol 6 ◽  
pp. CMO.S10773 ◽  
Author(s):  
Maurizio Iacoangeli ◽  
Alessandro Di Rienzo ◽  
Niccolò Nocchi ◽  
Lorenzo Alvaro ◽  
Maurizio Gladi ◽  
...  
Keyword(s):  
Unusual Complication ◽  
Non Hodgkin Lymphoma ◽  
Clinical Onset ◽  
Pathological Conditions ◽  
Stabilization Procedure ◽  
Long Term Follow Up ◽  
Rod Migration ◽  
Vertebral Stabilization

Paravertebral titanium rod migration represents an unusual and potentially fatal complication of vertebral stabilization surgical procedures. This condition, which requires a prompt and rapid diagnosis, is often mistaken for other more common diseases, or scotomized. We present a case of a 69 years old female affected by a non-Hodgkin lymphoma with evidence of migration of both rods five years after the posterior stabilization procedure for a pathological L3 fracture. Unusual clinical onset was represented by a left S1 radiculopathy without other symptoms. For several months, the symptoms were attributed to a possible radicular infiltration by the lymphoma. We conclude that paravertebral rod migration could happen not only within the spinal canal, but could also rarely damage blood vessels or parenchymal organs. This is generally a long-term complication, probably due to an insufficient fixation. Strict long-term follow-up monitoring is mandatory since this unusual complication can mimic other more common pathological conditions.

scholarly journals Migration of the Anterior Spinal Rod to the Right Thigh, a Rare Complication of Anterior Spinal Instrumentations: A Case Report and a Literature Review

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Camino Willhuber Gaston ◽  
Taype Zamboni Danilo ◽  
Carabelli Guido ◽  
Barla Jorge ◽  
Sancineto Carlos
Keyword(s):  
Rare Complication ◽  
Spinal Instrumentation ◽  
Unusual Complication ◽  
Anterior Fusion ◽  
Long Term Follow Up ◽  
The Right ◽  
Rod Migration ◽  
Surgical Treatments

Posterior and anterior fusion procedures with instrumentation are well-known surgical treatments for scoliosis. Rod migration has been described as unusual complication in anterior spinal instrumentations; migration beyond pelvis is a rare complication. A 32-year-old female presented to the consultant with right thigh pain, rod migration was diagnosed, rod extraction by minimal approach was performed, and spinal instrumentation after nonunion diagnosis was underwent. A rod migration case to the right thigh is presented; this uncommon complication of spinal instrumentation should be ruled out as unusual cause of sudden pain without any other suspicions, and long-term follow-up is important to prevent and diagnose this problem.

scholarly journals Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-up of the Pivotal Zuma-1 Trial

2018 ◽  
Vol 24 (3) ◽  
pp. S74-S75 ◽  
Author(s):  
Sattva S. Neelapu ◽  
Frederick L. Locke ◽  
Nancy L. Bartlett ◽  
Lazaros J. Lekakis ◽  
David Miklos ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Long Term Follow Up

90Yttrium-Ibritumomab-Tiuxetan As First-Line Therapy Or As Consolidation Treatment In Advanced Stage Follicular Non-Hodgkin Lymphoma: Long-Term Results After a Median Follow-Up Of 61 Months

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5123-5123
Author(s):  
Katharina Troppan ◽  
Angelika Valentin ◽  
Werner Linkesch, MD
Keyword(s):  
Advanced Stage ◽  
First Line ◽  
Ibritumomab Tiuxetan ◽  
Consolidation Treatment ◽  
Non Hodgkin Lymphoma ◽  
First Line Therapy ◽  
Significant Difference ◽  
Long Term Follow Up

Abstract Purpose Radioimmunotherapy combines biologic and radiolytic mechanisms to target and destroy tumor cells. 90Y-Ibritumomab-Tiuxetan (90YIT) is a murine anti-CD20 monoclonal antibody engaged for radioimmunotherapeutic targeting of CD20+ lymphoma cells. We report on our long-term follow-up data of 90YIT as first-line or consolidation treatment in advanced stage follicular Non-Hodgkin lymphoma (FL). Patients & Methods Between March 2004 and October 2010, forty-seven patients with CD20+ FL grade 1 to 3a in stages II, III, or IV were treated with a single dose of 90Yttrium-Ibritumomab-Tiuxetan (90YIT) at our institution. The median age was 61 years (range 41-83; male 55%) and 77% (n=36) of patients were in an advanced stage of the disease (stage III/IV). 90YIT was administered on an outpatient basis on day 8 after pretreatment with Rituximab (250mg/m²) on day 1. A mean of 1122 MBq (range 680-240) 90YIT was administered. Fourteen patients received 90YIT as first-line therapy, twenty-seven patients were treated with 90YIT after a median of 2 pretreatment courses (range 1-5) as consolidation therapy in remission (15 patients in CR, 12 patients in PR), and six patients showed progressive disease (PD) at time of 90YIT treatment. Median follow-up was 61 months (range 0-111). Results After a median follow-up of 61 months (range 0-111 months), 32 patients are still alive, including 21 patients in CR since 90YIT treatment. There was no significant difference concerning PFS and OS between first-line treatment and consolidation treatment, but we found a significant difference, comparing these two groups versus PD (PFS 51 months vs. 48 months vs. 8 months, p<0.023; OS 59 months vs. 71 months vs. 10 months, p<0.002) (figure 1 & 2). Survival rates were 85% (first-line), 67% (consolidation) and 33% (PD), respectively. Patients who maintained a CR after 90YIT treatment, showed significantly longer OS compared to patients with relapse after 90YIT (71 months vs. 52 months, p<0.001). No significant difference in PFS and OS was seen, concerning sex, age, or clinical stage. No unexpected toxicities emerged during long-term follow-up. Conclusion 90YIT as first-line, as well as consolidation therapy after achieving at least PR, provides a cost-efficient, long progression-free and overall survival in advanced stage FL. No benefit is shown in patients with PD, where we don't recommend 90YIT treatment. Disclosures: No relevant conflicts of interest to declare.

scholarly journals First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

2019 ◽  
Vol 37 (12) ◽  
pp. 984-991 ◽  
Author(s):  
Ian W. Flinn ◽  
Richard van der Jagt ◽  
Brad Kahl ◽  
Peter Wood ◽  
Tim Hawkins ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Time To Event ◽  
Free Survival ◽  
Non Hodgkin Lymphoma ◽  
Mantle Cell ◽  
Duration Of Response ◽  
Long Term Follow Up

PURPOSE The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma. This publication provides long-term follow-up data. PATIENTS AND METHODS Patients were monitored for a minimum of 5 years after completion of study treatment for the time-to-event end points of progression-free survival (PFS), event-free survival, duration of response, and overall survival per investigator assessment. Data on the number of patients who received second-line anticancer treatment and the occurrence of other malignancies were also collected. RESULTS The medians were not reached for any of the time-to event end points for either the BR or R-CHOP/R-CVP study treatment groups by study completion. PFS rates at 5 years were 65.5% in the BR treatment group and 55.8% in the R-CHOP/R-CVP group. The difference in PFS was considered significant with a hazard ratio of 0.61 (95% CI, 0.45 to 0.85; P = .0025). The hazard ratio for event-free survival and duration of response ( P = .0020 and .0134, respectively) also favored the BR regimen over R-CHOP/R-CVP. However, no significant difference in overall survival was observed. The overall safety profiles of BR, R-CHOP, and R-CVP were as expected; no new safety data were collected during long-term follow-up. A higher number of secondary malignancies was noted in the BR treatment group. CONCLUSION Overall, BR demonstrated better long-term disease control than R-CHOP/R-CVP and should be considered as a first-line treatment option for patients with indolent and mantle-cell lymphoma.

Long Term Follow-Up of 198 IgM Monoclonal Gammopathy of Undetermined Significance (MGUS).

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4859-4859
Author(s):  
Ombretta Annibali ◽  
Maria T. Petrucci ◽  
Francesco Bartolozzi ◽  
Anna Levi ◽  
Patrizia Del Bianco ◽  
...  
Keyword(s):  
Lymphoproliferative Disorder ◽  
Lymphocytic Leukaemia ◽  
Great Majority ◽  
Lymphoproliferative Disease ◽  
Non Hodgkin Lymphoma ◽  
Risk Of Progression ◽  
Long Term Follow Up ◽  
History Of

Abstract MGUS is found in more than 1 % of people 50 years or older and in approximately 3% of those older than 70 years. Of these the great majority are of IgG or IgA type while IgM MGUS are less frequent.The aim of this study was to analyse the natural history of IgM MGUS and the risk of progression to lymphoproliferative disorders. From July 1973 to June 2004, we observed 323 monoclonal gammopathies of IgM type. At diagnosis, 198 (61%) were MGUS, 111 (34%) were Waldeström’s Macroglobulinemia (WM) of whom 11 were pretreated, 8 (2,4%) were non Hodgkin Lymphoma (NHL), 5 (1,5%) were IgM Myeloma and only 1 was a chronic lymphocytic leukaemia. Of 198 patients with IgM MGUS, 125 (63%) were men and 73 (37%) were women ( ratio 1.71).Median age at diagnosis was 65.7 (range 33–89 years). At diagnosis, all patients had an IgM concentration less than 2 gr/dl with a median of 1.7 g/dl. Median Hb, serum creatinine and albumin levels were: 13.2 gr/dl, (range 6.9–17.9), 1,04 mg/dl ( range 0.6– 2,5) and 3.9 gr/dl ( range 2.4–5). Hepatomegaly as well as splenomegaly were present in 24% and 14% of patients, respectively. The 198 patients were monitored for 8741 months/person (median 25 months, range 0–411). During The follow up a lymphoproliferative disorder developed in 17 (8.5%) patients. In particular 11 pts (5.5%) pts evolved to WM and 6 (3%) to NHL. Progression incidence to linfoproliferative disorders was 0.001 months/person. Cumulative incidence of progression to lymphoproliferative disease was 1.3 % at 1 years, 6.8 % at 5 years, 23.2% at 10 years and 45.4% at 15 years. In conclusion the patients with IgM MGUS are more likely to die of unrelated diseases than to have progression to a malignant lymphoproliferative disorder.

Long-Term Follow-Up of a Patient with Spondylodiscitis after Laparoscopic Sacrocolpopexy: An Unusual Complication with a Review of the Literature

2018 ◽  
Vol 103 (3) ◽  
pp. 364-368 ◽  
Author(s):  
Funda Gungor Ugurlucan ◽  
Cenk Yasa ◽  
Omer Demir ◽  
Seniha Basaran ◽  
Baris Bakir ◽  
...  
Keyword(s):  
Unusual Complication ◽  
Laparoscopic Sacrocolpopexy ◽  
Review Of The Literature ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document